THU-278 Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model
The DOI matches its Crossref record.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, Kostadinova et al. utilised the proprietary AI imaging platform FibroNest (PharmaNest, US) to study the effects of anti-fibrotic compounds in 3D MASH models using Sirius red staining.31 They validated the tool on known anti-fibrotic compounds, showing its potential in drug discovery.31”
From Use of artificial intelligence for liver diseases: A survey from the EASL congress 2024 (2024) · cites this paper as [31]
Citations
Cites
Still being checked.
Cited by
Use of artificial intelligence for liver diseases: A survey from the EASL congress 2024
Žigutytė, L., Sorz-Nechay, T., Clusmann, J., & Kather, J. N. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101209 · Cited by 33
Metadata
- Authors
- Kostadinova, R., Ströbel, S., Chen, L., Fiaschetti-Egli, K., Gadient, J., Pawlowska, A. P., Petitjean, L., Bieri, M., Thoma, E., & Petitjean, M.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2024-06
- Volume
- 80
- Pages
- S590
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W4399459250
- Cited by
- 1
- References
- 0
- Citations by year
- 2024: 1
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Journal of Hepatology (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Keywords
- digital pathology, artificial intelligence, liver fibrosis, drug efficacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: THU-278 Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model. https://app.cochat.ai/papers/10.1016/s0168-8278(24)01732-x
- The paper
- Kostadinova, R., Ströbel, S., Chen, L., Fiaschetti-Egli, K., Gadient, J., Pawlowska, A. P., Petitjean, L., Bieri, M., Thoma, E., & Petitjean, M. (2024). THU-278 Digital pathology with artificial intelligence analysis provides insight to the efficacy of anti-fibrotic compounds in human 3D MASH model. Journal of Hepatology. https://doi.org/10.1016/s0168-8278(24)01732-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.